Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
This clinical trial, sponsored by M.D. Anderson Cancer Center, aims to evaluate the safety and efficacy of CAR.70-engineered IL15-transduced cord blood-derived NK cells in combination with lymphodepleting chemotherapy for patients with relapse/refractory hematological malignancies. The targeted patient population includes those with specific CD70 expression, which may represent a significant market opportunity given the high unmet need in hematological cancers such as leukemia, lymphoma, and multiple myeloma. The trial's focus on a novel CAR NK cell therapy positions it competitively within the expanding field of cell therapies, particularly against existing therapies that may not effectively target CD70-expressing tumors. Successful outcomes could lead to further development and commercialization, potentially enhancing M.D. Anderson's reputation as a leader in innovative cancer treatments.
Indication: B-Cell Lymphoma
Modality: small molecule
Target: CD70-targeted CAR NK cells engineered with IL15 transduction for enhanced anti-tumor activity.
Sponsor: M.D. Anderson Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD70-targeted CAR NK cells engineered with IL15 transduction for enhanced anti-tumor activity.
View original source fields
Condition raw: B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
Condition normalized: B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CD70-targeted CAR NK cells engineered with IL15 transduction for enhanced anti-tumor activity.
Target normalized: CD70-targeted CAR NK cells engineered with IL15 transduction for enhanced anti-tumor activity.